Part,  Chapter, Paragraph

 1    -,     1            |       Grant Agreement n. 2005115) (ii) produced through a 3-year
 2    -,     1            |            the Report development; ii) with the participation
 3    -,     1            |       sections: (i) Introduction; (ii) Data sources; (iii) Data
 4    I,     2.  1        |           i) higher productivity; (ii) higher labour supply;(iii)
 5   II                   |                               PART IIHEALTH CONDITIONS~
 6   II,     5.  3.  2    |           com.fr/~ ~EUROCHIP I and II: The EUROCHIP project is
 7   II,     5.  3.  2    |        puDeliverable01.php~ ~MOSES II: The European Society for
 8   II,     5.  3.  9    |       Europe Survey (MOSES). Phase II. htt 1 (document online,
 9   II,     5.  4.  2    |           m2~14~ ~HES/HIS Registry~II Epidemiology of diabetes~ ~ ~
10   II,     5.  4.  2    |         Countries with~recent data~II Epidemiology of diabetes~ ~
11   II,     5.  4.  8    |         Revealing the cost of Type II diabetes in Europe. Diabetologia,
12   II,     5.  5.Int    |          the field of employment; (ii) Actions under the European
13   II,     5.  5.Int    |        security policy, the DAPHNE II programme combats violence
14   II,     5.  5.  3    |         established~ by 24 months~ II 120 months (no AED; First
15   II,     5.  5.  3    |     unprovoked seizure (6 months)~ II 60 months (taxi 120; Must
16   II,     5.  5.  3    |       years~Estonia I 24 months -~ II - Prohibited~Finland I 12
17   II,     5.  5.  3    |        months)~ Myoclonias (dose)~ II - Prohibited~France I 12
18   II,     5.  5.  3    |        Seizures only on awakening~ II 24-60 months No seizures
19   II,     5.  5.  3    |     Treatment stop (ban 3 months)~ II 60 months (no AED) First
20   II,     5.  5.  3    |          year~Italy I 24 months -~ II - Prohibited~Netherlands
21   II,     5.  5.  3    |        stop/change (ban 3 months)~ II 60 months (no AED; Untreated
22   II,     5.  5.  3    |         particular~ circumstances~ II 120 months (taxi) -~Sweden
23   II,     5.  5.  3    |         Single unprovoked seizure~ II 60 months (taxi) -~Switzerland
24   II,     5.  5.  3    |           established~ by 3 years~ II 120 months (no AED) Medical
25   II,     5.  5.  3    |            Non commercial driving; II = Commercial driving;~AED =
26   II,     5.  5.  3    |       health services and society, ii) the cost of PD markedly
27   II,     5.  5.  3    |          or financial assistance; (ii) living as a couple in the
28   II,     5.  6.  6    | psychiatric illness: the Whitehall II Study. Soc Sci Med 40:189-
29   II,     5.  8.  3    |          suggested COPD GOLD stage II was 10.1% overall, 11.8%
30   II,     5.  8.  3    |            of gender, and at stage II or higher at 10.7%. A doctor
31   II,     5.  8.  3    |          respectively for stage I, II and III of the diseases.~ ~
32   II,     5.  8.  3(27)|           FEV1 80% predicted~Stage II:~Moderate FEV1/FVC <0.70~
33   II,     5.  8.  4    |           1% for GOLD stages I and II+, respectively (De Marco
34   II,     5.  9.  2    |  administered questionnaire. Phase II of ISAAC (in a large number
35   II,     5.  9.  2    |        rhinitic symptoms. In stage II, in a smaller random sample
36   II,     5.  9.  2    |    challenge were performed. ECRHS II is a nine year follow-up
37   II,     5.  9.  3    |         Asthma ever in ECHRS phase II and ISAAC phase I by country.~ ~
38   II,     5.  9.  4    |   Dermatophagoides pteronyssinus; (ii) timothy grass; (iii) cat; (
39   II,     5.  9.  4    |      cross-sectional study (SIDRIA II study, (Migliore et al,
40   II,     5. 11.  6    |        skin disease is very common ii) some skin diseases such
41   II,     5. 12.  4    |           France, during World War II, when both alcohol consumption
42   II,     5. 14.  3    |        International Collaborative II studiesexperience difficulty
43   II,     6.  3.  3    |           declined after World War II thanks to the widespread
44   II,     7.  5        |         the health policy agenda; (ii) to develop injury surveillance
45   II,     8.  2.  1    |         the Final Report of Pomona II will provide detailed information
46   II,     9.  2.  5    |          adequate sanitationRPG II: ensure protection from
47   II,     9.  4.  5    |          or financial assistance; (ii) living as a couple in the
48  III,    10.  1.  3    |        alcohol and other problems. II: The intergenerational effects
49  III,    10.  2.  1    |           the general population; (ii) problem drug use; (iii)
50  III,    10.  2.  1    |            child health policies; (ii) to develop and implement
51  III,    10.  2.  1    |     chronic diseases, such as type II diabetes and hypertension
52  III,    10.  2.  1    |           be added to foods. Annex II is a list of the sources
53  III,    10.  2.  1    |          the forms listed in Annex II, may be added to foods.~ ~
54  III,    10.  2.  1    |            informed choices. Annex II of this Directive is a list
55  III,    10.  2.  1    |       minerals not listed in Annex II has been prohibited since
56  III,    10.  3.  1    |         skin phototype (type I and II), a large number of naevi
57  III,    10.  3.  2    |            number of majorSeveso II accidents” (see below) reported
58  III,    10.  3.  2    |          enforcement of the Seveso II directive on major accident
59  III,    10.  3.  2    |           by the EEA.~ ~The Seveso II Directive, adopted in 1996
60  III,    10.  3.  2    |         Seveso in 1976. The Seveso II Directive was broader in
61  III,    10.  4.  2    |        e.g. withdrawal or recall; (ii) information notifications,
62  III,    10.  4.  2    |            withdrawal or recall); (ii) information notifications,
63  III,    10.  4.  2    |       Regulation 396/2005:~· Annex II deals with MRLs established
64  III,    10.  4.  2    |           the latest draft Annexes II and III which specify the
65  III,    10.  4.  2    |           feed and food.~ ~Chapter II of the Regulation seeks
66   IV,    11.  6.  2    |          higher income or Category II patients), Luxembourg and
67   IV,    11.  6.  2    |         Finland, Ireland (Category II patients) and Belgium (Thomson
68   IV,    11.  6.  5    |            G (2005): Mental health II: Balancing institutional
69   IV,    12.  5        |          list that will serve Part II - Health policies and action
70   IV,    12.  6        |          patientsorganizations; (ii) organizations representing
71   IV,    12. 10        |            Cocaine~Use in Ireland: II published in march 2007~
72   IV,    12. 10        |        dealing with (i) children, (ii) older people and (iii)
73   IV,    13.  7.  3    |            research institutions; (ii) competitiveness in top